One rapidly burgeoning meat market megatrend, as it is being called by some, is that of lab-grown meat—no animals yet organically grown meats nonetheless. The trend has already been making waves in recent years, but it’s growth is greatly catalyzed by Tyson’s sizable investment in Israeli biotech, Future Meat Technologies.
OurCrowd is a leading, crowd equity platform based in Jerusalem with branches in the U.S., Canada, Singapore and Australia. The firm just wrapped up its biggest investor conference, which involved an exhibition of the latest robotics, drones, medtech, AI, and mobility tech. Jon Medved, CEO of OurCrowd, made headlines with his announcement that OurCrowd raised $650 million, anticipating that they will soon break the $1 billion ceiling this year.
In a sign of deepening relationships between Israel and Canada, the Chief Scientist of Israel’s Ministry of Economy announced investment in three new joint research projects in the field of energy together with Canadian partners.
While much attention has been given to Israeli start-ups sold on to multinational technology companies, there are also a considerable number of growth companies who have built themselves up and are ready to trade publicly rather than run for high-profile exits, according to a new study by IVC Research Center.